Kahyaoglu Serkan, Ozaksit Muzeyyen Gulnur, Kahyaoglu Inci, Filiz Ahmet Arif, Pekcan Meryem Kuru, Atalay Ece, Tekin Ozlem Moraloglu
Department of Reproductive Endocrinology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
Department of Reproductive Endocrinology, Etlik Zubeyde Hanim Women's Health and Education Hospital, University of Health Sciences, Ankara, Turkey.
J Hum Reprod Sci. 2022 Oct-Dec;15(4):357-361. doi: 10.4103/jhrs.jhrs_121_22. Epub 2022 Dec 30.
Previous studies have revealed menstrual changes following coronavirus disease-19 (COVID-19) disease. The potential impact of COVID-19 on female reproductive organs, ovary in particular, has not been investigated thoroughly.
The aim of this study was to evaluate changes in serum levels of follicle-stimulating hormone (FSH), luteinising hormone (LH) and oestradiol (E2) following COVID-19 disease as a surrogate for the detection of ovarian vulnerability to SARS-CoV-2 infection.
In this retrospective study, hospital records of unexplained infertile women between 21 and 40 years old who have attended our institution's reproductive medicine unit for evaluation and/or treatment of infertility have been evaluated.
Menstrual cycle day 2-5 serum follicle-stimulating hormone, luteinising hormone and E2 levels of 28 infertile women have been studied both before and after the COVID-19 disease to evaluate ovarian reserve before the ovulation induction treatment cycle.
The demographic characteristics and hormonal results of these 28 unexplained infertile women have been compared. The Shapiro-Wilk test has been used to evaluate the normal distribution of variables. Comparison of ovarian reserve markers which were established before and after COVID-19 infection has been performed using paired samples -test.
All patients except one have shown mild COVID-19 symptoms and their infection courses have resulted in uneventful recovery. Serum FSH, LH and E2 levels of 24 (85%) and serum anti-Müllerian hormone (AMH) levels of 4 (15%) patients have been evaluated before and after COVID-19 disease is statistically similar.
COVID-19 disease or inflammatory response of the infection itself does not seem to affect pituitary gonadotropins and ovarian hormones in infertile women based on menstrual cycle day 2-5 serum FSH, LH, E2 and AMH levels. Further studies including higher patient numbers are urgently needed to clarify the potential effects of COVID-19 disease on the gonadal function of women.
先前的研究揭示了新型冠状病毒肺炎（COVID-19）疾病后的月经变化。COVID-19对女性生殖器官，尤其是卵巢的潜在影响尚未得到充分研究。
本研究的目的是评估COVID-19疾病后血清促卵泡生成素（FSH）、促黄体生成素（LH）和雌二醇（E2）水平的变化，以此作为检测卵巢对SARS-CoV-2感染易感性的替代指标。
在这项回顾性研究中，对21至40岁因不明原因不孕而到本机构生殖医学科进行不孕评估和/或治疗的女性的医院记录进行了评估。
研究了28名不孕女性在COVID-19疾病前后月经周期第2 - 5天的血清促卵泡生成素、促黄体生成素和E2水平，以评估排卵诱导治疗周期前的卵巢储备。
比较了这28名不明原因不孕女性的人口统计学特征和激素结果。采用夏皮罗-威尔克检验评估变量的正态分布。使用配对样本t检验对COVID-19感染前后建立的卵巢储备标志物进行比较。
除1名患者外，所有患者均表现出轻度COVID-19症状，其感染过程均顺利康复。24名（85%）患者的血清FSH、LH和E2水平以及4名（15%）患者的血清抗苗勒管激素（AMH）水平在COVID-19疾病前后经统计学分析相似。
基于月经周期第2 - 5天的血清FSH、LH、E2和AMH水平，COVID-19疾病或感染本身的炎症反应似乎不会影响不孕女性的垂体促性腺激素和卵巢激素。迫切需要开展包括更多患者的进一步研究，以阐明COVID-19疾病对女性性腺功能的潜在影响。
